Beliefs, Attitudes, and Interest in Genetic Testing in Sarcoma Patients (SPORE)
Genomic research has shown that a portion of leiomyosarcomas can be attributed to an underlying cancer predisposition syndrome. However, the optimal approach for incorporating germline testing into the care of these patients is not yet established. This study will assess beliefs about the heritability of leiomyosarcoma (LMS) and other cancers, and attitudes toward germline testing among LMS patients.
研究概览
地位
条件
详细说明
This is a descriptive study to explore attitudes toward genomics and interest in receiving personal genetic information among patients with leiomyosarcoma (LMS). The study aims to:
- Assess LMS patients' beliefs and attitudes about the heritability of LMS.
- Assess LMS patients' interest in genetic testing and their preferences for receiving information about genetic testing.
Prior studies of cancer patients have found strong interest in germline genetic testing to inform personal and familial cancer risk. However, germline genetic testing is not widely recommended for patients diagnosed with LMS, and little is known about patients' beliefs about the heritability of LMS or their interest in genetic testing. This study will use a survey to assess beliefs about the heritability of LMS, interest in genetic testing, and preferences for receiving information about genetic testing.
Participants will be identified by querying the Enterprise Data Warehouse (EDW) and the Huntsman Tumor Registry, recruiting in clinics at the Huntsman Cancer Institute, receiving referrals from providers outside the Huntsman Cancer Institute, and through LMS patient support and advocacy organizations.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Gregg Wood
- 电话号码:801-646-4215
- 邮箱:gregg.wood@hci.utah.edu
学习地点
-
-
Utah
-
Salt Lake City、Utah、美国、84112
- 招聘中
- Huntsman Cancer Institute at the University of Utah
-
接触:
- Wendy K Kohlmann, MS
- 电话号码:801-587-5556
- 邮箱:wendy.kohlmann@hci.utah.edu
-
首席研究员:
- Wendy K Kohlmann, MS
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
The study population will be Patients with a confirmed or self reported diagnosis of LMS
描述
Inclusion
- Living
- Able to speak and read English or Spanish
- Mentally competent
- Age 18 or older
Exclusion
- <18 years
- Unable to read or write
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
|---|
|
Patients with leiomyosarcoma
Electronic questionnaire assessing beliefs about the heritability of LMS and interest in genetic testing |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Beliefs about the heritability of Leiomyosarcoma
大体时间:up to 1 day from study enrollment
|
This outcome will describe LMS patients' beliefs about the heritability of LMS as well as other cancers, diseases, and physical traits. A five point Likert scale is used to classify conditions from totally inherited to totally environmental. |
up to 1 day from study enrollment
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Interest in germline genetic testing
大体时间:up to 1 day from study enrollment
|
This outcome will report interest in genetic testing for cancer predisposition for themselves as well as for other people such as family members, children, and the general public. Likert scales will be used to assess general interest in genetics and genetic testing in general. Interest in genetic testing will also be assessed with questions about when in the lifespan testing should be offered and for which types of conditions. |
up to 1 day from study enrollment
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Preferences for receiving information about genetic testing.
大体时间:up to 1 day from study enrollment
|
This outcome will report the count of participants who self reported sources for genetic testing information as helpful. Participants will rank questions about sources of information from "1 Not helpful at all" to "6 Extremely helpful" on their baseline questionnaire. Participants who reported >5 on this scale are considered to have found the source for genetic testing information as helpful. This outcome will assess information presented in tables and graphs and information presented numerically . |
up to 1 day from study enrollment
|
合作者和调查者
调查人员
- 首席研究员:Wendy Kohlmann, MS、Huntsman Cancer Institute
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Deidentified IDP will be shared with the University of Michigan Rogel Cancer Center for data analysis.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.